Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Donna H, Deacon"'
Autor:
Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan, Craig L. Slingluff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS),
Externí odkaz:
https://doaj.org/article/a8026c4ba7c5475c8be9506d9626cbab
Autor:
Craig L. Slingluff, James W. Patterson, Lynn T. Dengel, Sofia M. Shea, Donna H. Deacon, Mark E. Smolkin, Jochen T. Schaefer, Gulsun Erdag
PDF file - 118K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e5e058f7590d93b0b02d025d5cd055
https://doi.org/10.1158/0008-5472.22394826.v1
https://doi.org/10.1158/0008-5472.22394826.v1
Autor:
Victor H. Engelhard, Craig L. Slingluff, Mark Conaway, Donna H. Deacon, Kara L. Cummings, Joel Pinczewski, A. Nicole Desch, Rebecca C. Obeng, Angela L. Zarling
Supplemental Figure 1. Sequence of pIRS-21097-1105 TCR chains. Supplemental Figure 2. Sequence of pCDC25b38-46 TCR chains. Supplemental Figure 3. Electroporation of IVT RNA encoding murine TCR chains results in functional cell surface expression of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::487c7ebd428a56baf90a2dda7f5c4ffb
https://doi.org/10.1158/0008-5472.22403447
https://doi.org/10.1158/0008-5472.22403447
Autor:
Marit M. Melssen, Alexander F. Koeppel, Donna H. Deacon, Gina R. Petroni, Craig L. Slingluff, Alexandra W. Hickman, Max O. Meneveau, Katia Sol-Church, Mark E. Smolkin, Joel Pinczewski, Karlyn Pollack, Stephen D. Turner
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2151-2164
The strength and durability of systemic anti-tumor immune responses induced by cancer vaccines depends on adjuvants to support an immunogenic vaccine site microenvironment (VSME). Adjuvants include water-in-oil emulsions with incomplete Freund's adju
Autor:
Ileana S. Mauldin, Joel Pinczewski, Craig L. Slingluff, Victor H. Engelhard, Amber N. Woods, Donna H. Deacon, Katie M. Leick, Marcus Bosenberg, S. Young
Publikováno v:
Cancer Immunol Immunother
Immune-cell infiltration is associated with improved survival in melanoma. Human melanoma metastases may be grouped into immunotypes representing patterns of immune-cell infiltration: A (sparse), B (perivascular cuffing), and C (diffuse). Immunotypes
Autor:
Nadejda V. Galeassi, Caroline Reed, Varinder Kaur, Kathleen Haden, Walter C. Olson, Kimberly A. Chianese-Bullock, Anna Dickinson, Emily H. Hall, Kelly T. Smith, William W. Grosh, Nolan A. Wages, Donna H. Deacon, Gina R. Petroni, Craig L. Slingluff, Nikole Varhegyi, Mark E. Smolkin, Lynn T. Dengel, Elizabeth M. Gaughan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundPeptide vaccines designed to stimulate melanoma-reactive CD4+ T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomple
Autor:
Marit M, Melssen, Karlyn E, Pollack, Max O, Meneveau, Mark E, Smolkin, Joel, Pinczewski, Alexander F, Koeppel, Stephen D, Turner, Katia, Sol-Church, Alexandra, Hickman, Donna H, Deacon, Gina R, Petroni, Craig L, Slingluff
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(8)
The strength and durability of systemic anti-tumor immune responses induced by cancer vaccines depends on adjuvants to support an immunogenic vaccine site microenvironment (VSME). Adjuvants include water-in-oil emulsions with incomplete Freund's adju
Autor:
William W. Grosh, Max O. Meneveau, Walter C. Olson, Donna H. Deacon, Gina R. Petroni, James W. Patterson, Kevin T. Lynch, Craig L. Slingluff, Elizabeth M. H. Woodson, Mark E. Smolkin, Kimberly A. Chianese-Bullock, Elise P. Salerno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundExperimental cancer vaccines are traditionally administered by injection in subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory depots. Injection of melanoma-derived peptides induces T cell responses; how
Autor:
Craig L. Slingluff, Nadejda V. Galeassi, Kelly T. Smith, Marit M. Melssen, Kimberly A. Chianese-Bullock, Mark E. Smolkin, Nolan A. Wages, Elizabeth M. Gaughan, Donna H. Deacon, Gina R. Petroni, Nikole Varhegyi, William W. Grosh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS), combined
Publikováno v:
Cancer Immunology, Immunotherapy. 66:33-43
Infiltration of non-small-cell lung cancer (NSCLC) by CD8+ T lymphocytes predicts improved patient survival; however, heterogeneity of intratumoral localization complicates this assessment. Strategies for tumor sampling may not accurately represent t